James Huang is the Founding Managing Partner of Panacea Venture. James has over 30 years of experience in the healthcare industry across Asia and the US. Prior to founding Panacea, James joined Kleiner Perkins in 2011 as a Managing Partner, focusing on life science investments in the Greater China region. Before that, James was a Managing Partner at Vivo Ventures and President of Anesiva, a biopharmaceutical company focused on pain-management treatments. James has also held a number of senior positions across business development, marketing, and R&D functions with world leading healthcare companies, including Tularik Inc. (acquired by Amgen), GlaxoSmithKline LLC, Bristol-Meyers Squibb, and ALZA Corp. (acquired by Johnson & Johnson).
James holds an M.B.A. from Stanford Graduate School of Business and a B.S. degree in chemical engineering from the University of California, Berkeley.
Benjamin joined Panacea Venture in 2018, he is a scientist, entrepreneur, investor and merchant banker. Most recently Benjamin served as the CEO of ImaginAb, Inc. a ventured backed company developing a cutting edge platform to address an urgent unmet need in immuno-oncology. Immediately before that, he was the Chairman and CEO of London based Immune Targeting Systems, Inc. leading the immune therapy company through significant strategic growth, innovative product development and establishing a presence in France and North America. Prior to returning to operational roles, he spent nine years as a Managing Director at Burrill & Company, a global life sciences venture firm where he evaluated investment opportunities and assisted a global clientele in completing licensing, partnering and M&A transactions. He also played a key role in establishing the Malaysian Life Sciences Fund I and served as a director. Earlier in his career as an R&D executive, he has experience in building talented research team in immunology, stem cell biology, genomics, gene therapy and molecular diagnostics in both biotechnology start-ups and multinational pharmaceutical companies including Roche Diagnostics and Novartis.
Ben received his academic training in Microbiology and Immunology at the University of Wisconsin-Madison and Stanford University. Benjamin resides in the San Francisco Bay Area.
Andrew Ng is a Partner with Panacea. Andrew has over 13 years of experience in the healthcare industry across Asia and the US. He has established the healthcare investment practice of VMS Group in 2017 and invested in 10+ growth-stage investments across the therapeutics, diagnostics, medical device and CRO/CDMO verticals.
Prior to joining Panacea, Andrew was responsible for the China Healthcare Equity Research at Barclays Capital based in Hong Kong. Before that, he was an investment banker covering healthcare clients across the Asia Pacific region at Barclays Capital with a focus in healthcare cross-border M&A. Andrew started his career as a management consultant at ZS Associate in the United States advising global pharma on sales & marketing strategy and operations.
Andrew holds an M.B.A from INSEAD, a M.Eng. degree and a B.S. degree in Operations Research & Engineering from Cornell University.
Nikki Zhang is a Partner with Panacea Venture. Nikki has over 12 years of extensive working experience in biotech, medical device and healthcare investment industries across Asia and the US. Since she started her venture career, Nikki has invested in 10+ early-to-growth stage companies across pharma/biotech, medical device, diagnostics and CRO/CDMO sectors.
Before joining Panacea, Nikki was a director at Kleiner Perkins, covering the firm’s healthcare investment and portfolio management in Asia. Prior to Kleiner Perkins, Nikki worked at Zimmer Biomet Inc. in the US, where she took multiple leadership roles to manage the company’s global trauma business, M&A and post-merger integration projects. Earlier in her career, Nikki was a business development manager at HUTCHMED, where she specialized in corporate strategy, business development and strategic partnership management.
Nikki holds an M.B.A. from The Fuqua School of Business of Duke University. She also received an M.A. in Biotechnology from Columbia University and a B.S. in Biochemistry from The University of Texas at Austin.
Jeffry Wu is a Partner with Panacea. Prior to joining Panacea, Jeffry worked for Johnson & Johnson’s corporate venture (JJDC) and private equity funds in the United States and China dedicated to life science investments. He is also a member of the CFA Institute and served on the board of several healthcare companies.
Jeffry has graduated from University of Science & Technology of China and holds a PhD degree from Columbia University in the US and an M.B.A from INSEAD in France.
Andrew Aherrera is a Partner at Panacea, and leads the fund’s public markets strategy that encompasses de novo investments in both publicly traded companies as well as crossover opportunities. Prior to joining Panacea, Andrew was previously Portfolio Manager of Ample Plus, a healthcare-dedicated crossover investment fund with a similar cross-border pedigree that he helped build from the ground up, while simultaneously maintaining an operational role spanning business development, alliance management, and capital markets efforts at the fund’s biotech incubation engine. Andrew began his investment career at RA Capital, primarily covering CNS, hepatology, and oncology therapeutic areas.
Andrew graduated from the combined MD/MBA program at Tufts University School of Medicine, where he garnered AOA Honors and matched into Plastic Surgery at New York Presbyterian/Weill Cornell & Columbia University Medical Centers.
Delia Ding is a Partner and Chief Financial Officer with Panacea. Delia is responsible for daily financial functions on fund operation. She is also a Finance Director at Kleiner Perkins Caufield & Byers China.
Before joining KPCB in the year of 2013, Delia Ding worked at KPMG Shanghai and KCS Management & Consultancy where she had more than 10 years advisory and management experience on financial, taxation and human resources areas.
Delia received her bachelor’s degree in Accounting from Tongji University in China.
Cheryl Bao is a Partner and Chief Legal Officer with Panacea. Prior to joining Panacea, Cheryl previously worked as an attorney at two prestigious US law firms’ Shanghai office for 11 years, focusing mainly on venture capital and private equity investment practice. Cheryl holds an LL.M degree from University of Pennsylvania School of Law and an LL.M/LL.B degree from Shanghai University of International Business and Economics. Cheryl is a New York licensed attorny and has passed the Chinese Judicial Examination.
Hai was a partner at Kleiner Perkins Caufield & Byers China before he co-founded Panacea Venture with his partner James Huang. Prior to joining KPCB China, Hai was a partner DT Capital responsible for investment in life science and healthcare, and a venture partner of SB China Venture Capital (SBCVC). His investment includes BGI Tech, Symap Medical, Precise Light, and NeuInvent Inc.
Hai was Senior Director of Strategic Planning and then Vice President of Corporate Communications at WuXi AppTec in Shanghai, he also served on the board of Chemspec International (NYSE: CPC) as an independent board director and the chairman of audit committee. Earlier Dr. Mi was a research scientist at Parke-Davis Pharmaceuticals and then a senior manager at Pfizer in US.
Hai obtained a Ph.D. in organic chemistry from New York University, an MBA from The University of Chicago Booth School of Business, and a B.S. in material science from Fudan University in Shanghai.
Dr. Jay Zhang joined Panacea Venture in 2018 as a Venture Partner. He is the Co-Founder & CEO of TriArm Therapeutics and Interim CEO of Tactiva Therapeutics. He previously was General Manager of Dragonboat Biopharmaceutical, and the Founding CEO of Dragon Sail Biopharmaceuticals. He led the R&D, business development, IND registration & clinical trial, manufacturing setup & construction, merger & acquisition.
Jay also worked as Senior Scientist, Associate Director, Director, Founder etc. in various biotech companies including NYU Medical Center, GenMetrics, Infogene, Hyseq Pharmaceuticals, Protogene Laboratories, Anesiva etc.
Jay received a PhD in Neuroscience/Genomics from the University of Utah and did his post-doctoral training in Genetics at Stanford University. Jay is based in Shanghai, Taipei and San Francisco Bay Area.
Dr Tang was most recently a Medical Officer and Clinical Reviewer in the General Medicine Branch of the Office of Tissue and Advanced Therapy, Center for Biologics Evaluation and Research, the United States Food and Drug Administration. As a Medical Officer, he was responsible for regulating submissions related to gene and cell therapies, polyclonal antibodies, selected vaccines and combination products. He specialized in the regulation of gene and immune therapies, stem cell therapies and orphan diseases. He has reviewed submissions covering all stages of clinical development from the pre-Pre IND (currently referred to as Interact) stage to Biologic License Applications. In addition to his review work, he also served on a FDA sponsored working group for renal replacement therapy (including xenotransplantation), coauthored a guidance document for genome editing (2018), and was involved in outreach activities with the biotech industry. Dr Tang was the recipient of the CBER Regulatory Scientist Achievement Award in 2017.
Prior to joining the FDA, Dr Tang was a veteran of the biotechnology industry with positions of increasing responsibility at Amgen, Vertex, Tularik, Isis, Amsterdam Molecular Therapeutics (currently UniQure) and Sangamo. He has successfully filed INDs and BLAs in the US and Clinical Trial Applications and Marketing Authorization Application in the European Union, respectively. He is experienced in clinical trial design, strategic planning, project management, and regulatory compliance.
Dr Tang obtained his M.D. from the Albert Einstein College of Medicine in New York City and his M.S. degree in organic chemistry from Tufts University. He completed his Internal Medicine training at the Los Angeles County-University of Southern California Medical Center and subspecialty training in Nephrology at the University of California, San Diego Medical Center. He also completed a post-doctoral research fellowship in Immunology at the Scripps Research Institute, La Jolla, CA. on the pathogenesis of immune mediated kidney diseases and renal fibrosis.
Katherine Cohen joined Panacea Venture in 2018 and is based in Vienna, Austria. She has over 25 years of experience in the biotech and pharmaceutical industry and is a certified European Patent Attorney. Before joining Panacea Venture, Dr. Cohen served as CEO at Hookipa Biotech AG (now Hookipa Pharma Inc.), where she was responsible for the company formation and Series A and B venture financing, and under her leadership Hookipa grew from a research start-up to a clinical stage company. Prior to Hookipa, Dr. Cohen was Senior Vice President for Corporate and Business Development at Intercell AG (now Valneva SE) where she played an important role in the growth of the company from a start-up to a successful public and commercial stage enterprise. Prior to her biotech entrepreneurial career, Dr. Cohen worked in academic research and industrial development at Sandoz/VIRCC.
Dr. Cohen earned her Ph.D. in Biology at the City University of New York and B.S. from Wuhan University in China.
Jimmy Lu is a Venture Partner with Panacea. Jimmy has over 35 years of venture capital, healthcare & high technology and general business / legal experience. Prior to joining Panacea, Jimmy worked at WI Harper Group as a managing director and senior partner. Jimmy also previously worked as a managing director and general partner at Acer Technology Ventures & iD Ventures and the General Counsel at The Acer Group.
Jimmy received a J.D. from the University of California, Berkeley, School of Law an M.B.A from Harvard University and a B.A. from Yale College.
Han Ying is a Venture Partner with Panacea. Dr. Ying is a 20-year biotech veteran specializing in cell therapy. He received postdoctoral training with Dr. Steve Rosenberg at NCI. He published research in the field of DNA vaccines while at MDNI (affiliated with UCLA). Dr. Ying was also a scientific co-founder of several biotech companies in the field of cell therapy.
Dr. Ying received a Ph.D from Stanford University, in California.
Michelle Chung is a Venture Partner with Panacea. Michelle has over 30 years of healthcare industry experience with significant commercial expertise encompassing senior marketing, new product planning/lifecycle and sales leadership roles across a variety of therapy areas.
Prior to joining Panacea, Michelle was Vice President of Marketing at Braeburn, a specialty biopharmaceutical company focused on the treatment of opioid addiction. Before that, Michelle served as Global Senior Director of COPAXONE for MS at Teva Pharmaceuticals, launched two pain management treatments at Iroko Pharmaceuticals and served as Senior Marketing Director at Anesiva, a biopharmaceutical company focused on pain management. Michelle also led the successful launch of the Type 2 Diabetes treatments, Avandia in the UK and Avandamet in the US while at GlaxoSmithKline.
Michelle holds a B.A. degree in Communications from Villanova University.
Nancy Donahue is a Venture Partner with Panacea. Nancy has over 30 years of experience in the healthcare industry, with significant commercial expertise covering sales, marketing, and executive leadership.
Prior to joining Panacea, Nancy was Vice President of Marketing at Braeburn, a specialty biopharmaceutical company focused on the treatment of opioid addiction. Before that, Nancy served as Global Senior Director of COPAXONE at Teva Pharmaceuticals and launched two pain management treatments at Iroko Pharmaceuticals. Nancy also served as Senior Vice President of Sales and Marketing at Anesiva, where she built and led the commercial organization. Nancy started her career at GlaxoSmithKline and during her 15-year tenure, she led the diabetes franchise and launched and grew Coreg into a billion-dollar cardiovascular brand.
Nancy holds a B.S. degree in Food Marketing from Saint Joseph’s University.
Rosemary Mazanet MD, PhD is a Venture Partner with Panacea Venture. Dr. Mazanet is a well-known investor and C-suite professional in Biotech. Trained as an internist and oncologist in the Harvard Hospitals, she moved to Amgen, Inc. in the 1990s where she led Clinical Development teams that conducted successful development programs leading to global product approvals. She subsequently moved to apply her expertise to the public equity markets in NY (Oracle Partners, Apelles LP Argenis LP), where she often supported portfolio company Management teams and served as a Director. She continues that consulting work currently through R Mazanet LLC, and currently serves as CSO or CMO for early stage companies.
In addition to being an Independent Director on corporate boards, she is an Emeritus Trustee at the University of Pennsylvania Health System (her alma mater) as well as serving as the Chair, Executive Advisory Board for the Wharton Leonard Davis Institute. She sits on the Executive Committee of Save Venice, Boston.